Clinical trials: Anemia, open to volunteers
Sickle Cell Disease
PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
This post-authorisation safety and efficacy study (PRECISE PASS) evaluates the use of Xromi® (hydroxycarbamide 100 mg/mL oral solution) in children aged 9 months to under 2 years with sickle cell disease (SCD).
- Trial name
- PRECISE (NCT06923111)
- Testing
- Xromi
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 180 people
- Sponsor
- Nova Laboratories Limited
Sickle Cell Disease
Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, and Quality of Life.
Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage.
- Trial name
- EXDRE2 (NCT06823219)
- Testing
- endurance training program
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autoimmune Hemolytic Anemia
Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 STAR-T cell therapy in…
- Trial name
- NCT07453836
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 13 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Background: Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemia.
- Trial name
- NCT01174108
- Testing
- Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease (SCD), Vaso-Occlusive Crises
Pleuropulmonary Ultrasound Imaging in Patients With Sickle Cell Disease in a Vaso-occlusive Crisis. "ECHODREP"
Introduction Sickle cell disease is the most common inherited genetic disorder in France and worldwide. Its main acute manifestation is vaso-occlusive crisis, a frequent reason for emergency department visits.
- Conditions
- Sickle Cell Disease (SCD), Vaso-Occlusive Crises, Acute Chest Syndrome
- Trial name
- ECHODREP (NCT07782489)
- Testing
- Pleuropulmonary ultrasound
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alpha-Thalassemia, Alpha Thalassemia Major
International Registry of Patients With Alpha Thalassemia
This is an international prospective registry of patients with Alpha thalassemia to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of…
- Conditions
- Alpha-Thalassemia, Alpha Thalassemia Major, Alpha Thalassemia Minor
- Trial name
- ATM Registry (NCT04872179)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
The purpose of this study is to evaluate the efficacy of low-dose vitamin C plus herbal medicine on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
- Trial name
- NCT06601283
- Testing
- Vitmain C plus herbal medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Anemia, Iron Deficiency, Uterine Bleeding
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department
The primary aim of this randomized trial is to assess the efficacy of IV Ferric Derisomaltose vs Oral Iron in the management of women with severe Iron Deficiency Anemia due to Uterine Bleeding in the emergency department.
- Trial name
- NCT05304442
- Testing
- Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric], Ferrous Sulfate 65 mg elemental iron (325 mg tablets)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Anemia, Iron Deficiencies
Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery
Postoperative anemia is highly prevalent among patients undergoing cardiac surgery and is associated with delayed functional recovery, increased morbidity, and impaired long-term outcomes.
- Conditions
- Anemia, Iron Deficiencies, Iron Deficiency Anemia, Cardiac Surgery
- Trial name
- NCT07238972
- Testing
- Ferric derisomaltose
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Yonsei University
Renal Anemia, Peritoneal Dialysis (PD)
Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients
This is a prospective multicenter randomized controlled clinical study. The goal of this clinical trial is to learn if intravenous iron isomaltoside injection use is equally effective and safe for the treatment of renal anemia in…
- Trial name
- NCT06830941
- Testing
- Iron isomaltoside, Ferrous succinate
- Volunteers
- 124 people
- Sponsor
- Xie Jingyuan, MD
Severe Aplastic Anemia, Aplastic Anaemia
A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.
- Conditions
- Severe Aplastic Anemia, Aplastic Anaemia, Hematopoietic Cell Transplant
- Trial name
- NCT07586735
- Testing
- BFCA conditiong regimen
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University People's Hospital
Anemia, Pregnant Women
Impact of mHealth Education on Hemoglobin Level Among Pregnant Women With Anemia in Rural Bangladesh.
Anemia in pregnancy can result in negative pregnancy outcomes, which are higher among pregnant women of rural Bangladesh. A cost-effective health education program is urgently needed to introduce, which will help to improve their…
- Trial name
- Mobile Health (NCT07310680)
- Testing
- mHealth education
- Where
- Bangladesh
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Hiroshima University
Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease.
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia, Transfusion Dependent Beta-Thalassaemia
- Trial name
- NCT06647979
- Testing
- autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Daniel Bauer
Iron-deficiency, Colorectal Cancer
Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer
This double-blinded clinical randomized trial with a 1:1 recruitment ratio between placebo and the active group will aim to investigate the effects of intravenously administered iron in non-anemic iron deficient patients on…
- Trial name
- NAIDIC (NCT05220800)
- Testing
- Iron(III)isomaltoside
- Where
- 3 sites in Denmark
- Volunteers
- 134 people
- Sponsor
- Zealand University Hospital
IDA - Iron Deficiency Anemia, Anemia
Iron Deficiency Anemia (IDA) and the Brain
This is a trial with an observational and an interventional arm, in patients with moderate to severe anemia and control subjects.
- Conditions
- IDA - Iron Deficiency Anemia, Anemia, Iron Deficiency Anemia, Anemia, Iron Deficiency
- Trial name
- IDA (NCT05929729)
- Testing
- Ferric derisomaltose, NovaFerrum
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
This study is researching an experimental drug called ALN-CFB. The study is focused on people with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are currently taking a complement component C5 inhibitor ("C5-inhibitor") and…
- Trial name
- NCT07187401
- Testing
- ALN-CFB
- Where
- 8 sites in Canada, South Korea and 1 more
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Anemic Iron Deficiency
Risk of Anemia and Effects of Oral Iron Therapy in Non-Anemic Iron-Deficient Women (18-55 Years)
This study investigates the risk of anemia development in women aged 18-55 years with non-anemic iron deficiency and evaluates the clinical effects of oral iron therapy.
- Trial name
- NAID-F (NCT07263529)
- Testing
- Dietary Intervention (2 months), Oral Elemental Iron (Ferrous Sulfate) 80 mg/day
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul University - Cerrahpasa
PNH - Paroxysmal Nocturnal Hemoglobinuria
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with…
- Trial name
- NCT07256301
- Testing
- EA5
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Lanyi Therapeutics Co., Ltd.
aHUS, Atypical Hemolytic Uremic Syndrome
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
- Trial name
- NCT07308574
- Testing
- Ravulizumab
- Where
- 12 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease
A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly deoxyribonucleic acid (DNA)) from the patient to treat his…
- Trial name
- NCT07708350
- Testing
- autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Daniel Bauer